Dr. Moskowitz on the ALCANZA Trial in CTCL
4 Bekeken
• 08/09/23
0
0
insluiten
administrator
abonnees
Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses the data that led to the approval of brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL).
Laat meer zien
Facebook Reacties
SORT BY-
Top Reacties
-
Laatste Reacties